Biotechnology

Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023

Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research SAN JOSE, Calif., Dec. 29, 2022 /PRNewswire/ -- Complete Genomics Inc(https://completegenomics.mgiamericas.com/), a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting...

2022-12-30 01:58 2286

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

- Patent covers more than 100 novel compounds targeting neurodegenerative diseases including Parkinson's and Alzheimer's - MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company d...

2022-12-29 23:25 2650

Duoning maintains supply chain stability with operation of factory in Wuxi

SHANGHAI, Dec. 29, 2022 /PRNewswire/ -- Wuxi Duoning Factory, one of the seven manufacturing sites owned by Duoning Biotechnology, has been put into operation recently. The factory, through producing culture media and filters, is designed to provide optimal and quality-controlled bioprocess solut...

2022-12-29 20:00 3116

Takeda Healthcare Philippines Inc Honored the Inspirational Award at the Asia Pacific Enterprise Awards 2022 Regional Edition

SINGAPORE, Dec. 28, 2022 /PRNewswire/ -- Enterprise Asia, the organizer of the Asia Pacific Enterprise Awards (APEA) 2022 Regional Edition, is pleased to recognize 25 exemplary business leaders and enterprises acrossAsia which excelled and showcased unparalleled resilience and growth despite theC...

2022-12-28 15:30 2503

Everest Medicines Commences Operations at its mRNA Vaccine Manufacturing Facility, Accelerating Evolution to a Fully-Integrated Biopharma

--Everest owns complete pharmaceutical and vaccine value chain from discovery, clinical development, manufacturing and commercialization-- --Localizes company's mRNA vaccine production, and helps meet urgent China and global demand for innovative vaccines and medicines-- SHANGHAI, Dec. 28, 2022 ...

2022-12-28 08:00 3319

The Top 3 Best Places to Work in Indonesia for 2022 revealed

JAKARTA, Indonesia, Dec. 27, 2022 /PRNewswire/ -- Novo Nordisk, AstraZeneca and Jardine Schindler Indonesia are recognized as the top 3 best places to work in Indonesia for 2022 according to the annual prestigious "Best Places to Work" certification program. Best Places to Work is an international...

2022-12-27 21:39 2776

Promising Singaporean Medtech Firm Osteopore Achieves Record Revenue, Enters New Markets and Operates in All Major Continents in 2022

SINGAPORE, Dec. 27, 2022 /PRNewswire/ -- Singapore-based Medtech Firm Osteopore announces their record revenue of$460,684 for Q3 CY22, an increase of 6.6% over the preceding quarter. As an extension of the same financial year, Osteopore has likewise broadened their regional operations to spanColo...

2022-12-27 20:37 3688

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Topline Phase 2 data from multiple hepatitis B viral (HBV) infection functional cure combination studies expected in the first half of 2023 Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical hol...

2022-12-27 20:00 3247

Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies

SHANGHAI, Dec. 27, 2022 /PRNewswire/ -- Ablaze Pharmaceuticals ("Ablaze") announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. ("Yonghe") to develop series of targeted radiopharmaceutical therapy ("TRT") products. Under the...

2022-12-27 10:00 2935

GeneQuantum and WuXi XDC Entered into Strategic Collaboration to Empower Innovative Bioconjugate Development

SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), ann...

2022-12-26 23:01 2725

CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in humans.

SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based inRochester, MN...

2022-12-26 21:00 3016

Pulnovo Medical will be attending JPM Healthcare Conference 2023

SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, will be attending the upcoming 41st J.P. Morgan Healthcare Conference 2023 to discuss the latest trends in innovative technologies and development strategies in the medical device secto...

2022-12-24 20:00 3997

JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL

Best Cell & Gene Therapy Acquisition 2022: Juniper Biologics/Kolon Life Science SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd , a science-led healthcare company focused on commercialising novel therapies, was awarded ...

2022-12-23 09:35 3083

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hem...

2022-12-23 08:30 3381

ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances

* Complete data from global Phase III ZIRCON study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) will be presented at American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (ASCO GU) inFebruary 2023 * Telix pipeline...

2022-12-22 06:04 2389

Nuevocor to Present at Biotech Showcase during JPM week and at Keystone Symposium on Heart Development and Disease

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- Nuevocor , a pre-clinical stage cardiac gene therapy company, announced today that it will be presenting at the Biotech Showcase during JPM week, taking place inSan Francisco, CA, USA from January 9 to 11, 2023. Nuevocor will als...

2022-12-21 22:00 2328

Medidata awarded International Innovation Award for Medidata Sensor Cloud

SINGAPORE, Dec. 21, 2022 /PRNewswire/ -- For the third consecutive year, Medidata, a Dassault Systèmes company, was awarded the International Innovation Award. This year, the Medidata Sensor Cloud won the award under the Service and Solution category. Sensor Cloud provides cutting-edge data inges...

2022-12-21 14:44 2254

QureBio Ltd. to Present its Q-1802 Clinical Phase Ⅰ Data at 2023 ASCO-GI Meetings

SHANGHAI, Dec. 20, 2022 /PRNewswire/ --  QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineeredBiopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, today announced that Phase Ⅰ Clinical D...

2022-12-21 10:30 2349

PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope

IRVINE, Calif., Dec. 21, 2022 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies to treat cancers and immune disorders, today announced that the first patient treated in its phase 1 relapsed or refractory B-cell Non-Hodgkin Lymphoma (r/r B-NHL) clinic...

2022-12-21 09:00 2262

Ascletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned

HANGZHOU and SHAOXING, China, Dec. 21, 2022 /PRNewswire/ -- The enrollment of the 52-week Phase II clinical trial of thyroid hormone receptor β (THRβ) agonist ASC41 developed in house by Gannex Pharma Co., Ltd., a wholly owned subsidiary of Ascletis Pharma Inc. (HKEX: 1672, "Ascletis"), for tr...

2022-12-21 08:00 2733
1 ... 133134135136137138139 ... 307